

INTERNATIONAL SEARCH REPORT

ational Application No

/IL2004/000461

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/47 A61K38/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, Sequence Search, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | KASOF G M ET AL: "Livin, a novel inhibitor of apoptosis protein family member" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 5, 2 February 2001 (2001-02-02), pages 3238-3246, XP002973441 ISSN: 0021-9258 page 3238 ----- -/-- | 1-7 |

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

13 September 2004

Date of mailing of the international search report

28/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Young, C

INTERNATIONAL SEARCH REPORT

ational Application No

/IL2004/000461

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | <p>LIN JIING-HUEY ET AL: "KIAP, a novel member of the inhibitor of apoptosis protein family"</p> <p>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,</p> <p>vol. 279, no. 3,</p> <p>29 December 2000 (2000-12-29), pages 820-831, XP002296037</p> <p>ISSN: 0006-291X</p> <p>the whole document</p> | 1-7 |
| X | <p>VUCIC DOMAGOJ ET AL: "ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas"</p> <p>CURRENT BIOLOGY,</p> <p>vol. 10, no. 21,</p> <p>2 November 2000 (2000-11-02), pages 1359-1366, XP002296038</p> <p>ISSN: 0960-9822</p> <p>the whole document</p> | 1-7 |
| X | <p>ASHHAB A Y ET AL: "Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern"</p> <p>FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL,</p> <p>vol. 495, no. 1-2,</p> <p>20 April 2001 (2001-04-20), pages 56-60, XP004235763</p> <p>ISSN: 0014-5793</p> <p>the whole document</p> | 1-7 |
| X | <p>DATABASE EMBL BIR7 sequence</p> <p>28 February 2003 (2003-02-28), XP002296040</p> <p>retrieved from EBI</p> <p>Database accession no. Q96CA5</p> <p>abstract</p> | 1-7 |
| Y | <p>DEVERAUX QUINN L ET AL: "Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases"</p> <p>EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB,</p> <p>vol. 18, no. 19,</p> <p>1 October 1999 (1999-10-01), pages 5242-5251, XP002170857</p> <p>ISSN: 0261-4189</p> <p>page 5249</p> | 1-26 |
| | -/-- | |

INTERNATIONAL SEARCH REPORT

ational Application No

/IL2004/000461

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | <p>SANNA M GERMANA ET AL: "IAP suppression of apoptosis involves distinct mechanisms: The TAK1/JNK1 signaling cascade and caspase inhibition"</p> <p>MOLECULAR AND CELLULAR BIOLOGY, vol. 22, no. 6, March 2002 (2002-03), pages 1754-1766, XP002296039</p> <p>ISSN: 0270-7306</p> <p>the whole document</p> <p>-----</p> | 1-26 |

INTERNATIONAL SEARCH REPORT

International application No.,

PCT/IL2004/000461

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:

a. type of material

☒

a sequence listing

☐

table(s) related to the sequence listing

b. format of material

☒

in written format

☒

in computer readable form

c. time of filing/furnishing

☒

contained in the international application as filed

☒

filed together with the international application in computer readable form

☐

furnished subsequently to this Authority for the purpose of search

2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments: